Last reviewed 2026-04-19 · How we verify

PMC-309 Dose Expansion

PharmAbcine · Phase 1 active Small molecule

PMC-309 Dose Expansion is a Small molecule drug developed by PharmAbcine. It is currently in Phase 1 development. Also known as: Mono and Combination therapy.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	PMC-309 Dose Expansion
Also known as	Mono and Combination therapy
Sponsor	PharmAbcine
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PMC-309 Dose Expansion CI brief — competitive landscape report
PMC-309 Dose Expansion updates RSS · CI watch RSS
PharmAbcine portfolio CI

Frequently asked questions about PMC-309 Dose Expansion

What is PMC-309 Dose Expansion?

PMC-309 Dose Expansion is a Small molecule drug developed by PharmAbcine.

Who makes PMC-309 Dose Expansion?

PMC-309 Dose Expansion is developed by PharmAbcine (see full PharmAbcine pipeline at /company/pharmabcine).

Is PMC-309 Dose Expansion also known as anything else?

PMC-309 Dose Expansion is also known as Mono and Combination therapy.

What development phase is PMC-309 Dose Expansion in?

PMC-309 Dose Expansion is in Phase 1.

Manufacturer: PharmAbcine — full pipeline
Also known as: Mono and Combination therapy

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing